The global landscape for therapeutics targeting IgG4-related disease is experiencing substantial expansion. Driven by an increasing prevalence of these autoimmune conditions and the presence of novel treatment therapies, the market is poised for remarkable opportunities in the foreseeable future. Key drivers propelling this growth include a increas